A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations

Shinji Kohsaka, Neerav Shukla, Nabahet Ameur, Tatsuo Ito, Charlotte K.Y. Ng, Lu Wang, Diana Lim, Angela Marchetti, Agnes Viale, Mono Pirun, Nicholas D. Socci, Li Xuan Qin, Raf Sciot, Julia Bridge, Samuel Singer, Paul Meyers, Leonard H. Wexler, Frederic G. Barr, Snjezana Dogan, Jonathan A. FletcherJorge S. Reis-Filho, Marc Ladanyi

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Rhabdomyosarcoma, a cancer of skeletal muscle lineage, is the most common soft-tissue sarcoma in children. Major subtypes of rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors. Whereas ARMS tumors typically contain translocations generating PAX3-FOXO1 or PAX7-FOXO1 fusions that block terminal myogenic differentiation, no functionally comparable genetic event has been found in ERMS tumors. Here we report the discovery, through whole-exome sequencing, of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components. Previous mutagenesis studies had shown that MYOD1 with a p.Leu122Arg substitution can block wild-type MYOD1 function and bind to MYC consensus sequences, suggesting a possible switch from differentiation to proliferation. Our functional data now confirm this prediction. Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and the development of targeted therapeutics.

Original languageEnglish (US)
Pages (from-to)595-600
Number of pages6
JournalNature Genetics
Volume46
Issue number6
DOIs
StatePublished - Jun 2014

Fingerprint

Embryonal Rhabdomyosarcoma
Phosphatidylinositol 3-Kinases
Mutation
Rhabdomyosarcoma
Neoplasms
Muscle Neoplasms
Alveolar Rhabdomyosarcoma
Exome
Consensus Sequence
Mutagenesis
Sarcoma
Skeletal Muscle
Transcription Factors

ASJC Scopus subject areas

  • Genetics

Cite this

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. / Kohsaka, Shinji; Shukla, Neerav; Ameur, Nabahet; Ito, Tatsuo; Ng, Charlotte K.Y.; Wang, Lu; Lim, Diana; Marchetti, Angela; Viale, Agnes; Pirun, Mono; Socci, Nicholas D.; Qin, Li Xuan; Sciot, Raf; Bridge, Julia; Singer, Samuel; Meyers, Paul; Wexler, Leonard H.; Barr, Frederic G.; Dogan, Snjezana; Fletcher, Jonathan A.; Reis-Filho, Jorge S.; Ladanyi, Marc.

In: Nature Genetics, Vol. 46, No. 6, 06.2014, p. 595-600.

Research output: Contribution to journalArticle

Kohsaka, S, Shukla, N, Ameur, N, Ito, T, Ng, CKY, Wang, L, Lim, D, Marchetti, A, Viale, A, Pirun, M, Socci, ND, Qin, LX, Sciot, R, Bridge, J, Singer, S, Meyers, P, Wexler, LH, Barr, FG, Dogan, S, Fletcher, JA, Reis-Filho, JS & Ladanyi, M 2014, 'A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations', Nature Genetics, vol. 46, no. 6, pp. 595-600. https://doi.org/10.1038/ng.2969
Kohsaka, Shinji ; Shukla, Neerav ; Ameur, Nabahet ; Ito, Tatsuo ; Ng, Charlotte K.Y. ; Wang, Lu ; Lim, Diana ; Marchetti, Angela ; Viale, Agnes ; Pirun, Mono ; Socci, Nicholas D. ; Qin, Li Xuan ; Sciot, Raf ; Bridge, Julia ; Singer, Samuel ; Meyers, Paul ; Wexler, Leonard H. ; Barr, Frederic G. ; Dogan, Snjezana ; Fletcher, Jonathan A. ; Reis-Filho, Jorge S. ; Ladanyi, Marc. / A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. In: Nature Genetics. 2014 ; Vol. 46, No. 6. pp. 595-600.
@article{3b6aad4df14d455083a3ee448eda73f5,
title = "A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations",
abstract = "Rhabdomyosarcoma, a cancer of skeletal muscle lineage, is the most common soft-tissue sarcoma in children. Major subtypes of rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors. Whereas ARMS tumors typically contain translocations generating PAX3-FOXO1 or PAX7-FOXO1 fusions that block terminal myogenic differentiation, no functionally comparable genetic event has been found in ERMS tumors. Here we report the discovery, through whole-exome sequencing, of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components. Previous mutagenesis studies had shown that MYOD1 with a p.Leu122Arg substitution can block wild-type MYOD1 function and bind to MYC consensus sequences, suggesting a possible switch from differentiation to proliferation. Our functional data now confirm this prediction. Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and the development of targeted therapeutics.",
author = "Shinji Kohsaka and Neerav Shukla and Nabahet Ameur and Tatsuo Ito and Ng, {Charlotte K.Y.} and Lu Wang and Diana Lim and Angela Marchetti and Agnes Viale and Mono Pirun and Socci, {Nicholas D.} and Qin, {Li Xuan} and Raf Sciot and Julia Bridge and Samuel Singer and Paul Meyers and Wexler, {Leonard H.} and Barr, {Frederic G.} and Snjezana Dogan and Fletcher, {Jonathan A.} and Reis-Filho, {Jorge S.} and Marc Ladanyi",
year = "2014",
month = "6",
doi = "10.1038/ng.2969",
language = "English (US)",
volume = "46",
pages = "595--600",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations

AU - Kohsaka, Shinji

AU - Shukla, Neerav

AU - Ameur, Nabahet

AU - Ito, Tatsuo

AU - Ng, Charlotte K.Y.

AU - Wang, Lu

AU - Lim, Diana

AU - Marchetti, Angela

AU - Viale, Agnes

AU - Pirun, Mono

AU - Socci, Nicholas D.

AU - Qin, Li Xuan

AU - Sciot, Raf

AU - Bridge, Julia

AU - Singer, Samuel

AU - Meyers, Paul

AU - Wexler, Leonard H.

AU - Barr, Frederic G.

AU - Dogan, Snjezana

AU - Fletcher, Jonathan A.

AU - Reis-Filho, Jorge S.

AU - Ladanyi, Marc

PY - 2014/6

Y1 - 2014/6

N2 - Rhabdomyosarcoma, a cancer of skeletal muscle lineage, is the most common soft-tissue sarcoma in children. Major subtypes of rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors. Whereas ARMS tumors typically contain translocations generating PAX3-FOXO1 or PAX7-FOXO1 fusions that block terminal myogenic differentiation, no functionally comparable genetic event has been found in ERMS tumors. Here we report the discovery, through whole-exome sequencing, of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components. Previous mutagenesis studies had shown that MYOD1 with a p.Leu122Arg substitution can block wild-type MYOD1 function and bind to MYC consensus sequences, suggesting a possible switch from differentiation to proliferation. Our functional data now confirm this prediction. Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and the development of targeted therapeutics.

AB - Rhabdomyosarcoma, a cancer of skeletal muscle lineage, is the most common soft-tissue sarcoma in children. Major subtypes of rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors. Whereas ARMS tumors typically contain translocations generating PAX3-FOXO1 or PAX7-FOXO1 fusions that block terminal myogenic differentiation, no functionally comparable genetic event has been found in ERMS tumors. Here we report the discovery, through whole-exome sequencing, of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components. Previous mutagenesis studies had shown that MYOD1 with a p.Leu122Arg substitution can block wild-type MYOD1 function and bind to MYC consensus sequences, suggesting a possible switch from differentiation to proliferation. Our functional data now confirm this prediction. Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and the development of targeted therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84901687144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901687144&partnerID=8YFLogxK

U2 - 10.1038/ng.2969

DO - 10.1038/ng.2969

M3 - Article

C2 - 24793135

AN - SCOPUS:84901687144

VL - 46

SP - 595

EP - 600

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 6

ER -